Mori, Satoshi http://orcid.org/0000-0002-7660-5562
Hagino, Hiroshi
Sugimoto, Toshitsugu
Tanaka, Shiro
Mitomo, Yuji
Takahashi, Kaito
Sone, Teruki
Nakamura, Toshitaka
Soen, Satoshi
Funding for this research was provided by:
Public Health Research Foundation
Asahi Kasei Pharma Corp.
Article History
Received: 2 March 2022
Accepted: 4 October 2022
First Online: 14 October 2022
Declarations
:
: All the procedures performed in this study were in accordance with the Clinical Trials Act of the Japanese Ministry of Health, Labor and Welfare and with the 1964 Helsinki declaration and its later amendments. The protocol was approved by the certified review board of Toranomon Hospital and the central ethics committee of the Adequate Treatment of Osteoporosis research group.
: Informed consent was obtained from all the individual participants included in the study.
: H. Hagino has received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd., and UCB Japan.T. Sugimoto has received research grants from Asahi Kasei Pharma Corp., Astellas Pharma, Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer, and Teijin Pharma Ltd., as well as consulting fees from Kissei Pharmaceutical Co., Ltd., Shimadzu Corp., and Takeda Pharmaceutical Co., Ltd.S. Tanaka has received lecture fees from Bayer Yakuhin, Amgen Astellas BioPharma K.K., and Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Daiichi Sankyo Company, Limited, Boehringer Ingelheim, Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health Labor and Welfare, the Japanese Ministry of Education, Science, and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development.T. Sone has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan, as well as consulting and/or lecture fees from Asahi Kasei Pharma, MSD, and Daiichi-Sankyo.T. Nakamura has received personal fees and other from Asahi Pharma, Teijin Pharma, Daiichi-Sankyo Pharma, UCB Pharma, Amgen Inc., Astellas Pharma, and Chugai Pharma, as well as personal fees and others from MERCK.S. Soen has received consulting fees, speaking fees, and/or honoraria from Asahi Kasei Pharma, Amgen, Astellas Pharma, Daiichi Sankyo, Eli Lilly Japan, Teijin Pharma, and UCB Japan.S. Mori, Y. Mitomo, and K. Takahashi have nothing to disclose.